Mark Robson

55PUBLICATIONS
592CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEnvironmental epidemiologyCancer geneticsDecision making
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (55)

|Oct 10, 2026
CDKPredict: a clinicogenomic model for risk-adapted therapeutic intervention in breast cancer.

|Oct 08, 2026
Universal Germline Genetic Testing after a Diagnosis of Cancer.

|May 05, 2026
Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.

|Mar 04, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

Anton Safonov, Minna Lee, David N Brown

|Jan 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Nadine M Tung, Mark E Robson, Tianyu Li

|Dec 17, 2025
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.

Hope S Rugo, David W Cescon, Mark E Robson

Pageof 10

Frequent Collaborators

14 joint publications

Yelena M Kemel

12 joint publications

David Solit

11 joint publications

Michael Walsh

11 joint publications

Michael F Berger